Loading…
Reported covered position: Chief Health Advisor, US Sen. Finance Comm. (2/16/21-11/15/2024); Senior Advisor, US Sen. Finance Comm. (5/6/19 - 10/1/19); Professional Staff, US Sen. Finance Comm. (2/5/2005-10/1/2010).
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Patients Deserve Price Tags Act
Client: ZELIS HEALTHCARE CORPORATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to healthcare payments, healthcare Transparency in Coverage regulations and legislation including S.2355/H.R.5582 - Patients Deserve Price Tags Act.
Patients Deserve Price Tags Act
Client: ZELIS HEALTHCARE CORPORATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to transparency in healthcare coverage, including H.R. 5582/S. 2355 - Patients Deserve Price Tags Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
HEALTHCARE DISTRIBUTION ALLIANCE via AKIN GUMP STRAUSS HAUER & FELD
2026 · third_quarter · Q3
Issues related to distributor-supported service models and related policy, including pharmacy services administrative organizations and management services organizations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZELIS HEALTHCARE CORPORATION via AKIN GUMP STRAUSS HAUER & FELD
2026 · third_quarter · Q3
Source: Senate LDA
| TEXAS ASSOCIATION FOR HOME CARE & HOSPICE |
| 2 |
| 2025 |
| TRANSMEDICS GROUP, INC. | 2 | 2026 |
| ALLIANCE FOR AGING RESEARCH | 1 | 2024 |
| CELLDEX THERAPEUTICS, INC. | 1 | 2025 |
| PIEDMONT HEALTHCARE INC. | 1 | 2025 |
| PRN SOFTWARE, LLC | 1 | 2026 |
Patients Deserve Price Tags Act
Client: ZELIS HEALTHCARE CORPORATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to transparency in healthcare coverage, including H.R. 5582/S. 2355 - Patients Deserve Price Tags Act.
Patients Deserve Price Tags Act
Client: ZELIS HEALTHCARE CORPORATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to healthcare payments, healthcare Transparency in Coverage regulations and legislation including S.2355/H.R.5582 - Patients Deserve Price Tags Act.
No Fees for EFTs Act
Client: ZELIS HEALTHCARE CORPORATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to electronic provider payments and transparency in coverage; Issues related to the reintroduction of H.R. 6487/S. 3805 - No Fees for EFTs Act (118th Congress).
No Fees for EFTs Act
Client: ZELIS HEALTHCARE CORPORATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to electronic provider payments and transparency in coverage; Issues related to the reintroduction of H.R. 6487/S. 3805 - No Fees for EFTs Act (118th Congress).
No Fees for EFTs Act
Client: ZELIS HEALTHCARE CORPORATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to electronic provider payments and transparency in coverage; Issues related to the reintroduction of H.R. 6487/S. 3805 - No Fees for EFTs Act (118th Congress).
No Fees for EFTs Act
Client: ZELIS HEALTHCARE CORPORATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to electronic provider payments and transparency in coverage; Issues related to the reintroduction of H.R. 6487/S. 3805 - No Fees for EFTs Act (118th Congress).
Issues related to healthcare payments, healthcare Transparency in Coverage regulations and legislation including S.2355/H.R.5582 - Patients Deserve Price Tags Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PRN SOFTWARE, LLC via AKIN GUMP STRAUSS HAUER & FELD
2026 · third_quarter · Q3
Issues related to prescription drug price transparency and real-time benefit tool.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WW INTERNATIONAL, INC. via AKIN GUMP STRAUSS HAUER & FELD
2026 · third_quarter · 3T
Issues related to expanded GLP-1 coverage; Issues related to the implementation of GLP-1 Bridge; Issues related to CMMI ACCESS and BALANCE models; Issues related to the expanded coverage of lifestyle and behavioral support services to achieve healthy outcomes for patients.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
HEALTHCARE DISTRIBUTION ALLIANCE via AKIN GUMP STRAUSS HAUER & FELD
2026 · third_quarter · RR
Issues related to distributor-supported service models and related policy.
ZELIS HEALTHCARE CORPORATION via AKIN GUMP STRAUSS HAUER & FELD
2026 · second_quarter · Q2
Issues related to transparency in healthcare coverage, including H.R. 5582/S. 2355 - Patients Deserve Price Tags Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
WW INTERNATIONAL, INC. via AKIN GUMP STRAUSS HAUER & FELD
2026 · second_quarter · Q2
Issues related to expanded GLP-1 coverage; Issues related to the implementation of GLP-1 Bridge; Issues related to CMMI ACCESS and BALANCE models; Issues related to the expanded coverage of lifestyle and behavioral support services to achieve healthy outcomes for patients.
Issues related to GLP-1 products, including coverage for GLP-1 products and related health services, including lifestyle and behavioral support services to achieve healthy outcomes for patients.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
RESMED CORP. via AKIN GUMP STRAUSS HAUER & FELD
2026 · second_quarter · Q2
Issues related to AI-enabled medical devices, sleep health, and the management and prevention of chronic disease.
Issues related to respiratory, cloud-connected sleep care, and chronic disease prevention in the Medicare program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Health & Human Services, Dept of (HHS), Vice President of the U.S.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via AKIN GUMP STRAUSS HAUER & FELD
2026 · second_quarter · Q2
Issues related to budget reconciliation; Issues related to Most Favored Nation pricing proposals; Issues related drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRANSMEDICS GROUP, INC. via AKIN GUMP STRAUSS HAUER & FELD
2026 · first_quarter · Q1
Issues related to organ transplantation and the organ transplantation system.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
WW INTERNATIONAL, INC. via AKIN GUMP STRAUSS HAUER & FELD
2026 · first_quarter · Q1
Issues related to GLP-1 products, including coverage for GLP-1 products and related health services; Issues related to expanded GLP-1 coverage, including Medicare and Medicaid coverage for GLP-1 products and related health services within CMMI models to achieve healthy outcomes for patients; Issues related to TrumpRx.
Issues related to expanded GLP-1 coverage, including Medicare and Medicaid coverage for GLP-1 products and related health and support services within CMMI models to achieve healthy outcomes for patients; Issues related to TrumpRx.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
MAYNE PHARMA (USA), INC. via AKIN GUMP STRAUSS HAUER & FELD
2026 · first_quarter · Q1
Issues related to federal coverage of contraception; Issues related to prescription drug pricing and distribution platforms.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
TRANSMEDICS GROUP, INC. via AKIN GUMP STRAUSS HAUER & FELD
2026 · first_quarter · RR
Issues related to updates to the National Organ Transplant Act (NOTA) of 1984 (P.L. 98-507).
ZELIS HEALTHCARE CORPORATION via AKIN GUMP STRAUSS HAUER & FELD
2025 · fourth_quarter · Q4
Issues related to electronic provider payments and transparency in coverage; Issues related to the reintroduction of H.R. 6487/S. 3805 - No Fees for EFTs Act (118th Congress).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, White House Office
WW INTERNATIONAL, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · fourth_quarter · Q4
Issues related to GLP-1 products, including coverage for GLP-1 products and related health services; Issues related to TrumpRx.
Issues related to expanded GLP-1 coverage, including Medicare and Medicaid coverage for GLP-1 products and related health services within CMMI models to achieve healthy outcomes for patients.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP)
RESMED CORP. via AKIN GUMP STRAUSS HAUER & FELD
2025 · fourth_quarter · Q4
Issues related to respiratory care in the Medicare program; Issues related to Medicare proposed rule for competitive bidding of Durable Medical Equipment (DME).
Issues related to respiratory care market and patient outcomes.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, Vice President of the U.S.
MAYNE PHARMA (USA), INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · fourth_quarter · Q4
Issues related to coverage of contraceptive products.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
WW INTERNATIONAL, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · fourth_quarter · RR
Issues related to GLP-1 products, including Medicare and Medicaid coverage or GLP-1 products and related health services.
Issues related to GLP-1 products, including Medicare and Medicaid coverage or GLP-1 products and related health services.
ZELIS HEALTHCARE CORPORATION via AKIN GUMP STRAUSS HAUER & FELD
2025 · third_quarter · Q3
Issues related to electronic provider payments and transparency in coverage; Issues related to the reintroduction of H.R. 6487/S. 3805 - No Fees for EFTs Act (118th Congress).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, White House Office
RESMED CORP. via AKIN GUMP STRAUSS HAUER & FELD
2025 · third_quarter · Q3
Issues related to respiratory care in the Medicare program; Issues related to Medicare proposed rule for competitive bidding of Durable Medical Equipment (DME).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB)
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via AKIN GUMP STRAUSS HAUER & FELD
2025 · second_quarter · Q2
Issues relating to drug pricing proposals including implementation of the Inflation Reduction Act (P.L. 117-169); Rx oversight issues; PBM oversight issues; Issues related to budget reconciliation; Issues related to Most Favored Nation proposals; Issues related to the FTC.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MAYNE PHARMA (USA), INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · second_quarter · Q2
Issues related to coverage of contraceptive products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TEXAS ASSOCIATION FOR HOME CARE & HOSPICE via AKIN GUMP STRAUSS HAUER & FELD
2025 · second_quarter · Q2
Issues related to regulations and legislative proposals affecting reimbursement and staffing for home care agencies, home care and hospice; Issues related to Medicaid budget reconciliation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
MAYNE PHARMA (USA), INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · second_quarter · RR
Coverage of Contraceptive Products.
PIEDMONT HEALTHCARE INC via AKIN GUMP STRAUSS HAUER & FELD
2025 · second_quarter · RR
Issues related to Medicaid direct payments.
TEXAS ASSOCIATION FOR HOME CARE & HOSPICE via AKIN GUMP STRAUSS HAUER & FELD
2025 · first_quarter · Q1
Issues related to home care and hospice, telehealth, Medicare reimbursement, workforce, 80/20 rule impact on HCBS, and legislative and regulatory proposals affecting home care and hospice.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
CELLDEX THERAPEUTICS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · first_quarter · RR
Issues related to biotechnology policy.
ALLIANCE FOR AGING RESEARCH via AKIN GUMP STRAUSS HAUER & FELD
2024 · fourth_quarter · Q4
Issues related to utilization management and changes to Medicare Part D.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE